Short Interest in Capricor Therapeutics Inc (NASDAQ:CAPR) Increases By 25.7%

Capricor Therapeutics Inc (NASDAQ:CAPR) saw a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 5,870,000 shares, a growth of 25.7% from the June 30th total of 4,670,000 shares. Based on an average daily volume of 430,600 shares, the short-interest ratio is currently 13.6 days.

Analyst Ratings Changes

CAPR has been the topic of several research analyst reports. StockNews.com cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. LADENBURG THALM/SH SH increased their price objective on Capricor Therapeutics from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, May 14th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday, July 2nd. Finally, Oppenheimer initiated coverage on Capricor Therapeutics in a research report on Friday, May 17th. They issued an “outperform” rating and a $14.00 price objective for the company. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.75.

Capricor Therapeutics Trading Down 1.4 %

Shares of NASDAQ:CAPR traded down $0.06 during midday trading on Friday, hitting $4.37. The company had a trading volume of 276,093 shares, compared to its average volume of 541,852. The firm has a fifty day simple moving average of $5.11 and a 200 day simple moving average of $5.13. The stock has a market cap of $139.75 million, a price-to-earnings ratio of -5.02 and a beta of 4.00. Capricor Therapeutics has a 12 month low of $2.68 and a 12 month high of $8.22.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.20). The company had revenue of $4.91 million during the quarter, compared to the consensus estimate of $10.00 million. Capricor Therapeutics had a negative net margin of 89.72% and a negative return on equity of 231.68%. Equities analysts forecast that Capricor Therapeutics will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds have recently bought and sold shares of CAPR. Vanguard Group Inc. raised its stake in Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after buying an additional 200,499 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares in the last quarter. Jump Financial LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at approximately $258,000. Finally, BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics during the 1st quarter worth approximately $40,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.